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ABSTRACT 
 
Regulation of mitosis through mitotic checkpoints is critical to prevent 
propagation of DNA damage and to ensure proper DNA content of the resulting 
daughter cells.  Loss of these checkpoint functions may lead to neoplasias or 
cancers.  The protein checkpoint with forkhead associated and RING domains 
(CHFR) has been implicated as a tumor suppressor in a multitude of cancers.  
Originally identified as a major component of the antephase checkpoint, CHFR 
has recently been associated with the spindle assembly checkpoint through its 
interaction with MAD2.  To further understand the role of CHFR in this 
checkpoint, we deleted key functional domains from the CHFR protein and 
investigated the effects on MAD2 binding and function.  We found that the C-
terminal cysteine-rich domain of CHFR is required for the CHFR/MAD2 
interaction.  In addition, this domain is important for MAD2 localization, 
interaction with CDC20, and prevention of chromosome segregation defects.  
These data indicate an important role for CHFR in the function of MAD2 and the 
spindle assembly checkpoint. 
CHFR loss is observed in a wide array of cancers, supporting its role as a 
tumor suppressor.  Most often, CHFR is lost via hypermethylation of the CHFR 
xiii 
gene promoter.  However hypermethylation is not observed in the majority of 
breast cancers.  Using a panel of breast cancer lines we explored the role of 
microRNA in reducing CHFR levels.  We found a correlation between expression 
of miR-26 and decreased transcription of CHFR, suggesting that this miRNA 
could target the CHFR mRNA to reduce protein levels.  These data suggest that 
miR-26 could be useful in the future as a biomarker indicating CHFR protein 
loss.
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CHAPTER 1 
Introduction 
 
Identification of cancer related genes and proteins that can serve as 
diagnostic, prognostic, and/or therapeutic biomarkers is essential to improve 
targeted management of cancer.  Because of the diversity of molecular pathways 
by which cancers arise, even within cancers of similar cellular origin, many 
markers, or combinations of markers will likely be required to accurately profile 
each case of cancer for accurate diagnosis and effective treatment.  CHFR 
(Checkpoint with Forkhead-associated domain and Ring finger), a cell cycle 
checkpoint regulator, has been attracting increased attention as a potential tumor 
suppressor and predictor of chemotherapy response.  CHFR was first reported in 
2000 as the result of a screen to identify cell cycle checkpoint proteins containing 
forkhead-associated (FHA) domains [1]. The identification of CHFR was most 
significant in that it defined a novel cell cycle checkpoint occurring at metaphase 
entry in response to microtubule stress brought on by nocodazole treatment [1]. 
CHFR was expressed in all normal human tissues tested, further supporting its 
important role in cell cycle control [1]. In addition, the authors found mutation or 
loss of CHFR expression in 50% of their tested cancer cell lines, implicating 
CHFR as a tumor suppressor [1]. Interestingly, the mitotic index of cell lines 
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lacking CHFR was significantly higher than the lines that retained CHFR 
expression, and re-introduction of CHFR into CHFR-lacking lines significantly 
reduced the mitotic index in these cells [1]. Since its discovery, CHFR has been 
the focus of extensive research to determine the cellular and clinical impact of its 
function, as well as the mechanism by which CHFR regulates the cell cycle. 
Decreased CHFR expression has been observed in a wide array of cancer 
types ranging from breast to urogenital tumors, suggesting that it has tumor 
suppressor-like properties [2].  In addition, the CHFR gene is located on 
chromosome 12q24, a site identified as a location of frequent chromosome 
rearrangements and allelic imbalance in some cancers [3].  Most often, reduced 
CHFR expression results from increased methylation of its gene promoter [2] but 
some cancers demonstrate CHFR loss without evidence of promoter 
hypermethylation [4]. Loss of CHFR expression has been shown to confer 
cellular characteristics associated with cancer, such as an accelerated growth rate, 
enhanced cell motility, increased invasiveness, and higher rates of aneuploidy [2, 
3, 5], which likely result, at least in part, from failed checkpoint arrest in cells that 
may already lack normal apoptotic mechanisms.  Accordingly, Chfr knockout 
mice have increased incidence of spontaneous and DMBA (7,12-
dimethylbenz(a)anthracene)-induced tumors [5].  The predisposition of Chfr-/- 
mice to tumors indicates that CHFR indeed functions as a tumor suppressor in 
vivo, and underscores the importance of CHFR in cancer progression.  Further 
understanding of CHFR regulation and function will likely lead to more detailed 
3 
diagnoses and better cancer treatments.  To this end, we undertook several 
studies of CHFR, two of which are described in this thesis.  In one, we explored a 
novel mechanism for the regulation of CHFR expression in breast cancer lines 
where CHFR is lost.  In the other, we chose to look closely at the functional 
domains of the CHFR protein and their role in the mitotic checkpoint function of 
CHFR.  
 
CHFR Protein Structure 
 CHFR contains five identified domains as illustrated in Figure 1.1.  The 
combination of FHA and RING domains is found in only one protein other than 
CHFR, namely RNF8 (Ring Finger Protein 8) [6].  The cysteine-rich domain, 
including the PBZ (Poly(ADP-ribose)-binding Zinc Finger)domain, is unique to 
CHFR among FHA-RING proteins [2, 6].  The known functions for each domain 
are discussed below. 
 
The forkhead-associated domain 
 CHFR was initially identified in a screen for proteins containing the 
forkhead-associated (FHA) domain [1]. The FHA domain is known to bind to 
phosphorylated threonine residues, and is found in proteins with several cellular 
functions, notably several cell cycle checkpoint proteins [6-8].  The FHA domain 
of CHFR has been shown to be critical for its checkpoint function, as a FHA 
deletion allele behaves as a dominant negative, increasing mitotic index in cells  
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Figure 1.1.  The domains of CHFR.  CHFR protein contains several domains.  The 
FHA domain is a phospho-threonine binding domain.  The KEN box domain 
may be involved in cell cycle stage-dependent degradation.  The RING domain is 
critical for the E3 ubiquitin ligase function of CHFR.  The cysteine-rich domain 
has been identified as the site of CHFR target protein binding, and contains the 
PBZ domain, a domain shown to bind PAR and possibly involved in CHFR 
substrate recognition. 
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that have been under mitotic stress [1, 9].  A splice variant of CHFR in which the 
exons encoding the FHA domain are deleted is expressed in very low levels in 
normal human tissues, but is highly expressed in cancer cell lines [10] (Figure 
1.2).  In addition, the FHA domain has been reported to be essential for proper 
nuclear localization of CHFR [11].  Structural analyses of the FHA domain of 
CHFR indicate that it is likely to bind phosphorylated substrates as predicted 
[12], however no binding partner has yet been identified. As the function of this 
domain is critical to the checkpoint function of CHFR, the target of the FHA 
domain on CHFR is an important unknown in the understanding of CHFR 
function. 
 
The KEN box domain 
 CHFR contains a putative KEN box domain, defined as the amino acid 
sequence lysine-glutamic acid-asparagine (K-E-N) [13, 14].  This putative motif is 
especially interesting for CHFR studies because it has been identified as a 
targeting signal for the anaphase promoting complex (APC) and is enriched in 
cell cycle proteins [13, 14].  The APC is a ubiquitin ligase thought to promote 
mitotic progression by degradation of its target proteins [14]. As there is some 
evidence that CHFR protein levels change throughout the cell cycle [15].  The 
presence of the KEN box domain on CHFR raises the possibility of cell stage-
specific degradation as a mechanism of CHFR regulation.  However, an 
interaction between APC and CHFR has not yet been demonstrated, and some 
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Figure 1.2.  CHFR splice variants.  Full length CHFR is illustrated, with splice 
variants of CHFR below it.  Locations of FHA and KEN box domains, which are 
lost in some splice variants, are indicated above.  RING, cysteine-rich and PBZ 
domains are preserved in all of the splice variants.  Adapted from Toyota et al 
[10] 
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evidence suggests that KEN box domains following the KENxP motif are the 
relevant domains for APC targeting [16]. However, CHFR does not fit this 
extended motif (the sequence in CHFR is KENVF), and two splice variants of 
CHFR (ΔEx6 and Ex6b) do not include the KEN box (Figure 1.2).  More work is 
required to determine the contribution of this motif to the cellular function of 
CHFR. 
 
The RING domain 
CHFR contains a RING finger (RING) domain, a domain commonly found 
in ubiquitin ligase proteins, which is required for CHFR E3 ubiquitin ligase 
activity [15, 17].  As with many E3 ligase proteins, CHFR is reported to interact 
with multiple E2 ubiquitin conjugating enzymes.  UBC4 and UBC5 were 
identified as E2 conjugating enzymes with which CHFR could auto-ubiquitinate, 
and UBC4 also functioned with CHFR to ubiquitinate PLK1 (Polo-like Kinase 1), 
which was then degraded [17].  CHFR was also shown to act in complex with 
UBC13-MMS2 in vitro, forming noncanonical Lys63-linked ubiquitin chains [18].  
Lys63-linked ubiquitin chains generally do not target proteins for degradation, 
but rather act as signaling modifications [18].  In addition, the RING domain, and 
therefore the ubiquitin ligase activity of CHFR, is required for the checkpoint 
function of CHFR, as deletion of the RING domain resulted in reduced viability 
of cells treated with taxol to induce microtubule stress [15].  Thus, the RING 
8 
finger of CHFR represents a critical domain for CHFR molecular and checkpoint 
functions. 
 
The cysteine-rich domain 
The C-terminus of the CHFR protein contains a large cysteine-rich domain 
which is unique to CHFR among FHA-RING containing proteins [1]. This 
domain appears to confer substrate specificity to CHFR as it has been identified 
as the domain required for its interaction with ubiquitination targets Aurora A, 
Kif22, HDAC1 and HLTF [5, 19-21].  The cysteine-rich domain contains zinc-
binding motifs including a PBZ often found in DNA-damage response and 
checkpoint proteins [22, 23].  This domain is further described below.  
 
The PBZ domain 
 The cysteine-rich domain of CHFR contains a poly(ADP ribose)-binding 
zinc finger (PBZ domain) [22, 23].  Poly(ADP ribose), or PAR, is a protein 
modification that is enriched at the mitotic spindle and at sites of DNA damage 
[24]. PAR is involved in the proper formation of the mitotic spindle, as well as 
mitotic spindle function [25, 26].  Mutation of the PBZ domain disrupts the early 
mitotic checkpoint function of CHFR [22].  Additionally, chemical inhibition of 
poly(ADP ribose) polymerase also disrupted the CHFR checkpoint, suggesting 
that this checkpoint function depends on CHFR recognition of ADP-ribosylated 
substrates [22].  Of interest, mutation of the PBZ domain abolished the dominant 
9 
negative activity of FHA-deleted CHFR [22].  This effect lends support to the 
hypothesis that the PBZ domain is the critical domain for CHFR substrate 
targeting, specifically after PAR modification.  As stated above, several CHFR 
substrates have been found to interact with CHFR via the cysteine-rich domain 
[5, 19-21].  The PBZ domain alone has not been evaluated for CHFR substrate 
targeting; thus it is possible that the binding of CHFR to these substrates is 
entirely dependent on the PBZ domain.  In this scenario, regulation of PAR 
polymerases (PARPs) could control CHFR activity in the mitotic checkpoint.  
Currently, no PAR-modified substrates of CHFR have been identified, but the 
role of the PBZ domain in CHFR function is an interesting question warranting 
further study.  
 
CHFR Cellular Functions 
 CHFR is an E3 ubiquitin ligase protein responsible for an early mitotic 
checkpoint [1, 2].  E3 proteins are critical in the ubiquitination signaling process 
as they provide substrate specificity, and function to recruit E2 ubiquitin 
conjugating proteins to the intended target.  The function of CHFR-dependent 
ubiquitination appears to be multifaceted.  Many CHFR ubiquitination substrates 
have been shown to be downregulated as a result, suggesting that they are 
targeted for degradation by this modification [5, 17, 19-21].  However, evidence 
in human cells as well as yeast indicate that CHFR can function with UBC13-
MMS2 to form lysine-63-linked polyubiquitin chains, which are generally 
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associated with non-degradative (noncanonical) ubiquitin signaling [18, 27].  
Evidence from yeast is consistent with this dual function of CHFR.  Yeast cells 
contain two homologs of human CHFR, Chf1 and Chf2 (a.k.a. Dma1 and Dma2), 
and these proteins have been shown to function with Ubc13-Mms2 to form 
lysine-63-linked ubiquitin chains, as well as with Ubc4 to catalyze canonical 
lysine-48-linked as well as lysine-63-linked ubiquitin chains [27, 28].  These data 
suggest a dual role for CHFR-controlled ubiquitination in both degradative and 
non-degradative regulation.  
The range of CHFR functions is not limited to its ubiquitination activity.  
CHFR has been implicated in several cellular processes, including the antephase 
and spindle assembly checkpoints.  In fact, CHFR was first identified as a 
checkpoint protein essential for its role in causing chromosome condensation 
delay due to microtubule stress before the entry into mitosis [1]. This work 
established CHFR as a component of the so-called novel “antephase” checkpoint 
which monitors microtubule dependent events between prophase and 
metaphase [1]. More recent studies have implicated CHFR in the spindle 
assembly checkpoint between metaphase and anaphase [5, 20, 29], which can 
also be triggered by microtubule-targeting drugs.  Given this, it is hypothesized 
that CHFR functions in two distinct cellular checkpoints during mitosis (Figure 
1.3) where CHFR functions to halt the cell cycle in response to microtubule 
damage or spindle defects, ensuring proper chromosome segregation and cell  
11 
 
 
 
Figure 1.3.  CHFR in the mitotic checkpoints.  CHFR was originally identified as 
a major component of the antephase checkpoint occurring prior to metaphase in 
response to microtubule stress.  Recent work has identified a role for CHFR later 
in mitosis at the spindle assembly checkpoint, which arrests cells prior to 
chromosome separation in anaphase.  Adapted from: The Cell: A Molecular 
Approach.  2nd ed. [38] 
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division [1, 2].  In addition, CHFR activity has been implicated in processes 
leading to metastasis and angiogenesis [21, 30].  
 
CHFR in the Antephase Checkpoint 
 The antephase checkpoint occurs at the end of G2, prior to prometaphase 
when cells are committed to mitosis, and is activated in response to microtubule 
stress [31, 32].  This checkpoint was defined by the discovery of CHFR, and cell 
lines lacking functional CHFR fail to activate this checkpoint [1, 31].  There is 
some evidence that this checkpoint occurs in response to a failure of the 
centromeres to properly separate [1], a critical step for assembly of a mitotic 
spindle. Extensive study of CHFR has revealed several CHFR targets implicated 
in mitotic progression in cells. 
Polo-like kinase-1 (Plk1) was the first ubiquitination target of CHFR 
identified [17].  Plk1 is a critical mitotic protein, which regulates cell cycle and 
mitotic entry [33].  Early studies identified Cyclin B1/Cdk1 activity as key 
activators of mitotic entry regulated by the CHFR checkpoint [1, 34].  PLK1 is 
known to promote mitotic entry through activation of its targets CDC25C and 
Cyclin B/Cdk1, and these targets are inhibited by CHFR [17, 35, 36].  
Furthermore, CHFR was shown to exclude Cyclin B1 from the nucleus, and 
expression of Cyclin B1 lacking nuclear export signal could bypass the early 
mitotic checkpoint [34]. CHFR could ubiquitinate Plk1 in Xenopus extracts, 
targeting Plk1 for degradation and delaying mitotic onset as measured by 
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histone H1 phosphorylation [17].  Since then, two publications have shown an 
inverse relationship between CHFR levels and Plk1 levels in mammalian cell 
lines, including Chfr knockout mouse embryonic fibroblasts (CHFR-/- MEFs) [5, 
37].  While Plk1 represents an interesting target for CHFR control of mitotic 
onset, more evidence is needed to strengthen the tie between these two proteins. 
CHFR’s dual checkpoint function may be carried out, at least in some 
cases, by CHFR-mediated ubiquitination/degradation of AurA (Aurora A 
kinase), a protein that drives mitotic progression [5, 39].  AurA is ubiquitinated 
by CHFR both in vitro, and in vivo ubiquitination of AurA is abolished in Chfr 
knockout cells [5].  While, the effect of CHFR on AurA levels has been 
questioned [34], Chfr knockout MEFs (Mouse Embryonic Fibroblasts) show a 
clear increase in AurA levels relative to MEFs derived from wild type littermates 
[5]. Aurora A is critical to the early stages of mitosis, and plays a role in mitotic 
entry as well as centrosome maturation and separation [40, 41].  AurA is required 
for the recruitment of several centrosome components, thought to be required for 
both centrosome function and migration to opposite poles [40]. In addition, 
Aurora A is critical for centrosome duplication and is also involved in the 
spindle assembly checkpoint [39].  
Loss of AurA inhibits proper bipolar spindle formation and results in 
mitotic arrest, while overexpression of AurA has been shown to induce 
multipolar spindle formation and is linked to oncogenic phenotypes such as 
aneuploidy [42, 43].  Similar phenotypes are seen when CHFR expression is 
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reduced, which increases AurA levels in the cell [5, 29].  AurA phosphorylates 
Cdc25B, a phosphatase required for Cyclin B/Cdk1 activation, and likely 
promotes mitotic entry in part through this modification [44].  AurA has also 
been shown to directly phosphorylate and activate polo-like kinase-1, another 
CHFR target, to promote mitotic entry [45, 46].  In addition to its G2/M 
functions, AurA appears to have some role in the spindle assembly checkpoint, 
as the checkpoint is bypassed in cells overexpressing AurA [47].   
 
CHFR in the Spindle Assembly Checkpoint 
The spindle assembly checkpoint delays progression through metaphase 
in response to unattached or improperly attached kinetochores.  Critical 
components of this checkpoint include the MAD and BUB proteins, which serve 
to delay sister chromatid separation until proper spindle attachment is achieved 
[48]. MAD2 (Mitotic Arrest Deficient 2) is of particular importance in that it 
targets CDC20, a component of the anaphase promoting complex (APC) to 
inactivate the APC and delay anaphase in response to unattached kinetochores 
[49, 50]. 
The involvement of CHFR in the spindle assembly checkpoint is a fairly 
recent discovery.  The interaction between CHFR and MAD2 implicated CHFR in 
this checkpoint, although several known CHFR targets may be involved at this 
stage of mitosis (such as AurA, mentioned above [47]).  Cells with reduced CHFR 
expression do not delay metaphase in response to spindle defects, but continue 
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mitosis resulting in mitotic defects such as failed nuclear separation, lagging 
chromosomes, and failed cytokinesis [1, 5]. 
MAD2, a protein that is recruited to unattached kinetochores to act in the 
spindle-assembly checkpoint during mitosis, has recently been shown to bind to 
CHFR protein in immortalized mammary epithelial cells [29, 51].  Loss of CHFR 
results in mislocalization of MAD2 and BUBR1, both of which bind to 
kinetochores and are critical for the spindle assembly checkpoint [29].  CHFR 
reduction disrupts the CDC20/MAD2 complex, which is hypothesized to free 
CDC20 to activate the anaphase-promoting complex, leading to progression 
through mitosis [29].  
CHFR has also been found to bind to TCTP (Translationally Controlled 
Tumor Protein), α-tubulin, and the chromokinesin Kif22, all thought to be 
components of the mitotic spindle [20, 29, 52].  TCTP has been connected to 
several cellular processes, most interesting regarding the mitotic spindle is its 
microtubule stabilizing effect [53].  It has been suggested that this binding of 
CHFR to TCTP or tubulin could be important for CHFR to sense microtubule 
stress and trigger the checkpoint [29, 52].  Studies of TCTP indicate that it may be 
involved in stabilizing the mitotic spindle microtubules, and regulation of TCTP 
may be necessary for returning the microtubules to a more dynamic state after 
metaphase [54].  
The role of α-tubulin in the mitotic spindle is clear, as α-tubulin is a major 
component of spindle microtubules.  As CHFR was originally identified as a 
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sensor of microtubule stress, the interaction between CHFR and α-tubulin could 
indicate the mechanism by which CHFR senses microtubule dysfunction.  In fact, 
the interaction between CHFR and α-tubulin was observed in MCF10A cells only 
after nocodazole treatment [29].  siRNA reduction of CHFR resulted in an 
increase in α-tubulin levels and a decrease in ubiquitinated α-tubulin, indicating 
that CHFR may play a role in α-tubulin stability [29].  In addition, reduction of 
CHFR increased the amount of acetylated α-tubulin, which is associated with 
more stable microtubules, and suggests a role for CHFR in regulating spindle 
microtubule dynamics [29, 55]. 
Kif22 is a chromokinesin that is involved in the alignment of 
chromosomes within the spindle [56].  CHFR targets Kif22 for degradation, and 
overexpression of Kif22 causes multipolar spindles and aneuploid cells, 
suggesting that CHFR regulation of Kif22 contributes to regulation of the mitotic 
spindle [20].  The interactions between CHFR and α-tubulin, TCTP, and Kif22 
suggest that CHFR has a physical interaction with the mitotic spindle, and that 
CHFR may regulate the mitotic spindle checkpoint directly, through Kif22, in 
addition to the checkpoint delay brought on by inhibition of the APC through 
MAD2. 
 
CHFR in Migration, Motility and Angiogenesis  
In addition to the widely recognized role of CHFR in mitotic checkpoint 
control, CHFR is known to interact with proteins involved in migration, 
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metastasis and angiogenic pathways.  siRNA reduction of CHFR in immortalized 
human mammary epithelial cell lines has been shown to increase cell motility 
and invasion into matrigel, while expression of CHFR in CHFR-lacking breast 
cancer lines has the opposite effect [3].  Support for the role of CHFR in these 
phenotypes can be found in studies identifying cellular targets of CHFR, 
specifically helicase-like transcription factor (HLTF) and histone-deacetylase 1 
(HDAC1) [19, 21].  HLTF regulates the transcription of the gene PAI-1, which 
controls cell motility [19, 57].  CHFR targets HLTF for degradation, and cells 
overexpressing HLTF show significantly higher motility, which can be reduced 
by CHFR expression [19]. Similarly, HDAC1 is thought to affect transcription of 
multiple genes involved in cell motility, and shRNA reduction of HDAC1 in 
cancer lines reduced the invasiveness of cells into matrigel [21].  These two 
ubiquitination targets implicate CHFR in pathways leading to motility and 
invasion, suggesting that CHFR could contribute to metastasis.  
Finally, CHFR has been shown to inhibit the transcription factor NF-κB, 
leading to suppression of several genes [30].  One NF-κB target, IL-8, is 
associated with cell motility as well as tumor angiogenesis, and a xenograft 
model demonstrated that CHFR expression reduced angiogenesis in tumor 
tissues [30].  These studies demonstrate that CHFR likely plays an extensive and 
complex role in cancer progression, and further understanding of CHFR and its 
targets will lead to a better understanding and treatment of cancers in the future. 
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CHFR and Cancer 
CHFR as a tumor suppressor 
 CHFR was initially characterized as a checkpoint protein that was lost in 
four of the eight human cancer cell lines initially tested (including colon cancer, 
osteosarcoma, and neuroblastoma cancer lines) [1].  Cell cycle checkpoint 
function insures proper segregation of chromosomes, and misregulation of 
mitotic checkpoints is understood to cause aneuploidy, a characteristic of many 
cancers [58].  In addition, reduction of endogenous CHFR in immortalized 
mammary epithelial cell lines resulted in the onset of tumor-like phenotypes 
such as aneuploidy, as well as increased mitotic index, growth rate, invasiveness, 
motility and soft agar colony formation [29].  In cancer cell lines that express little 
or no CHFR, restoration of CHFR expression reduced the mitotic index, 
invasiveness, motility, and growth rate of the cells [29].  
CHFR is connected to cancer-related phenotypes through its downstream 
targets and interacting proteins (Figure 1.4).  The CHFR targets connected to the 
antephase and mitotic spindle checkpoints, such as AurA, PLK1, MAD2 and 
CyclinB1/Cdc2, are important for growth control and prevention of aneuploidy 
[17, 42, 58-60].  HLTF has been shown to modulate expression of PAI-1 to 
regulate cell migration [19], and HDAC1 is associated with motility and 
invasiveness of cells, linking it to metastasis in breast cancer [21, 61]. Finally, NF-
κB is implicated in enhancing progression through the cell cycle, promoting 
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Figure 1.4.  The role of CHFR in the cell cycle and neoplastic processes.  CHFR 
loss has been implicated in several cancer progression-related phenotypes.  
CHFR has been shown to target HDAC1 and HLTF for degradation, linking 
CHFR loss to metastasis.  CHFR expression in some cancer lines reduced NF-κB, 
and reduced angiogenesis in a xenograft model.  In addition, several 
downstream effectors of CHFR involved in mitotic checkpoint processes have 
been identified.  PLK1, Aurora A, and KIF22 are ubiquitination targets of 
CHFR[5, 17, 20], MAD2, α-tubulin and TCTP have been shown to interact with 
CHFR, and CyclinB1/CDC2 appears to be regulated by CHFR expression.  Loss 
of the antephase and spindle checkpoints results in more rapid growth and 
increased aneuploidy when CHFR is lost. 
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angiogenesis and preventing apoptosis through its transcriptional regulation of a 
wide array of genes [30, 62]. 
The strongest data in support of CHFR as a tumor suppressor protein 
comes from analysis of the Chfr knockout mouse.  Chfr-/- mice had increased 
incidence of skin tumors after exposure to the carcinogen DMBA, as well as 
spontaneous development of lymphomas and epithelial tumors of major organs 
[5].  Embryonic fibroblasts isolated from these mice also displayed chromosome 
instability, consistent with previous knockdown studies of CHFR [3, 5].  In 
addition, the Chfr-/- MEFs were able to form colonies in culture, a characteristic of 
cellular transformation [5].  For these reasons, CHFR is considered a tumor 
suppressor protein likely to play an important role in the progression of many 
cancer types. 
While mutation of CHFR is not found in many cancer cells, loss of CHFR 
protein is a frequent occurrence [2, 63].  One polymorphism (V539M) located in 
the cysteine-rich domain was reported to be strongly associated with colorectal 
cancer risk [64].  Loss of CHFR protein expression has been reported in a wide 
range of cancer types, including breast, lung, colorectal, and ovarian cancers [2]. 
The majority of these cancer types show evidence that this loss is due to CHFR 
promoter hypermethylation, however breast cancers appear to be the exception 
[2, 4, 65].  Clearly, CHFR loss represents an important step in the progression of  
several cancers, and therefore could have clinical significance as a prognostic and 
therapeutic biomarker. 
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CHFR as a biomarker of malignancy 
While decreased and/or lost CHFR expression is implicated in cancer 
progression, it also represents a promising biomarker for cancer treatments.  The 
status of CHFR, as well as related proteins, in a given tumor may be informative 
for microtubule targeting drug therapies.  Cell lines in which CHFR expression 
has been inhibited show reduced survival and increased apoptosis when treated 
with microtubule-targeting drugs [29, 66, 67].  Additionally, many studies have 
shown correlations between loss of CHFR expression and tumor progression 
phenotypes, such as tumor size, invasion, differentiation and tumor stage, in 
cancers of different origins (Table 1.1).  CHFR loss is associated with increased 
malignant potential and poor outcomes [2].  CHFR loss has been associated with 
advanced tumor stage in hepatocellular carcinomas [68] and head and neck 
squamous cell carcinomas [69], but is found in all stages in gastric and 
esophageal cancers [70].  
One of the challenges in treating cancers is that many chemotherapeutics 
are effective in only a subset of patients.  In order to provide the best outcomes, it 
is important to have methods to determine the best course of treatment for each 
individual case.  Because cancers arise from a variety of genetic changes, 
treatment choices may be optimized based on the genetic features of the cancer 
cells.  This represents a powerful tool by which physicians can choose the most 
effective treatment for their patients.  A strong correlation between CHFR loss 
and sensitivity to microtubule drugs such as paclitaxel has been demonstrated in 
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NSCLC (non-small cell lung cancer) [71], suggesting that CHFR promoter 
methylation could be used as a predictive marker of drug response. However, 
work by Yoshida et al suggests that, in advanced and recurrent gastric cancer, 
CHFR promoter methylation does not predict response to paclitaxel [72].  This 
may indicate that gastric cancers often contain other mutations that counteract 
the paclitaxel sensitivity conferred by CHFR loss.  Thus, additional markers may 
be required to determine proper drug response.  Recently, Takeshita et al 
presented evidence that the combination of CHFR methylation status, EGFR 
mutation status and patient smoking habit can more effectively predict tumor 
response to paclitaxel treatment in NSCLC [71]. Therefore, CHFR represents an 
important marker for sensitivity to microtubule-specific chemotherapeutics.
CHFR promoter methylation alone may not be informative enough as a 
predictor of chemoresponsiveness in all cancers.  The invasiveness of the 
procedure necessary to determine CHFR promoter methylation status in lung 
cancers (and likely other solid tumors) make CHFR-based predictions less than 
ideal in NSCLC [71]. In addition, CHFR promoter methylation does not appear to 
be the cause of CHFR protein loss in breast cancers [2, 4, 65].  This indicates the 
importance of finding alternate indicators for drug response.  Other related 
genes, such as SIRT2, a tubulin deacetylase that is involved in the same 
antephase checkpoint processes as CHFR and lost in gliomas [86], or PLK1, 
which is lost in many cancer types [17], may be predictive of chemotherapeutic 
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Cancer origin Loss of CHFR associated with: 
Breast 
 
Increased tumor size [3] 
Estrogen receptor negative [3] 
Gastric Poor differentiation [73, 74]* 
Increased sensitivity to paclitaxel (in culture) [75, 76]† 
Microsatellite instability [77] 
Increased tumor size [74] 
Lung Smoking habit [78, 79] 
Increased tumor size [78] 
Poor differentiation [78, 79] 
Lymphatic invasion [79] 
Poor prognosis [78, 79] 
Peripheral nerve 
sheath 
High mitotic count [80] 
Poor prognosis [80] 
Colorectal Microsatellite instability [81] 
Increased recurrence [82] 
Liver Advanced stage [68] 
Infiltrative growth [68] 
Endometrial Increased sensitivity to taxanes [83] 
Cervical Increased sensitivity to taxanes (in culture) [84] 
Head and neck Late stage [69] 
 
 
Table 1.1.  CHFR loss associated with human cancer phenotypes.  Listed are 
cancer types in which CHFR loss has been observed, and the clinically relevant 
phenotypes associated with CHFR loss.  
*Disputed in [85] †Disputed in [72]
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response to paclitaxel similarly to CHFR methylation status.  While CHFR 
appears to be a promising biomarker for cancer progression and 
chemotherapeutic response, significant work is still needed to fully understand 
the prognostic and chemotherapeutic impact of CHFR loss in cancers. 
  
Investigating the Regulation and Function of CHFR 
In order to further the understanding of CHFR, we have explored both the 
function of CHFR in regulating mitotic checkpoints and a potential novel 
mechanism for regulating CHFR protein expression.  First, we investigated the 
interaction between CHFR and MAD2 in the mitotic spindle checkpoint.  As both 
CHFR and MAD2 have been implicated in cancers [2, 87, 88], understanding the 
relationship between these proteins, physical interactions as well as functional, 
could lead to better understanding of the processes leading to cancer and 
influence treatments based on the molecular signature of each cancer.  We 
focused on the major functional domains of CHFR in order to gain insight into 
the mechanism by which CHFR interacts with MAD2 and regulates the spindle 
assembly checkpoint, and also how that mechanism relates to previously 
identified functions of CHFR in the antephase checkpoint and toward other 
substrates.  First, we confirmed the interaction between CHFR and MAD2 in a 
human cell line as well as mouse embryonic fibroblasts.  We then identified the 
cysteine-rich domain of CHFR as required for interaction with Mad2, while the 
RING domain was dispensable for this interaction.  In addition, interaction with 
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CHFR appears to be required for proper MAD2 localization and spindle 
assembly checkpoint function, lending support to the evidence that CHFR 
functions in the spindle assembly checkpoint in addition to the antephase 
checkpoint.  Interestingly this function does not appear to depend on the RING 
or FHA domains, which have been identified as critical to the antephase 
checkpoint and for ubiquitination of downstream substrates (discussed above).  
These results suggest that CHFR has multiple functions, some dependent on the 
E3 ubiquitin ligase function while some, as in the case of MAD2, independent of 
this function. 
 We also examined the possible role of microRNA regulation in CHFR 
expression changes, specifically focusing on breast cancer lines in which CHFR 
mRNA and protein levels do not correlate as expected.  CHFR loss has been 
demonstrated to result in cancer progression phenotypes in breast and other 
cancers, and restoration of CHFR expression in BCC lines lacking CHFR 
ameliorates several of these phenotypes [2, 3, 29].  CHFR loss is observed in 
many breast cancer lines, indicating that loss of CHFR may be a major event in 
breast tumorigenesis [3].  Furthermore, no explanation currently exists for the 
mechanism by which CHFR is lost in breast cancers.  Understanding this 
mechanism may lend insight into tissue-specific events unique to breast tissue 
and/or breast cancer, and allow better understanding of the differences between 
breast cancers and other cancers.  Promoter methylation of CHFR is currently 
being explored as a biomarker for CHFR loss in other cancers, and has, in some 
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cases been correlated to chemotherapeutic response to paclitaxel [89]. In the same 
way, understanding the mechanism underlying CHFR loss in some breast 
cancers may be useful in biomarker development.  In addition, new treatment 
options may be possible targeting the cause of CHFR loss, to restore CHFR 
expression in tumor cells.  We show evidence that one microRNA, miR-26, could 
be inhibiting translation of CHFR mRNA, implicating the microRNA as a 
mechanism of CHFR regulation.  As miR-26 has been previously implicated in 
several cancer types, it may prove to be important for cancer progression 
through CHFR loss.  
 
Notes 
Parts of this chapter were previously published as: 
J.A. Keller, A.E. Erson-Bensan, and E.M. Petty, Connections between CHFR, the 
cell cycle, and chemosensitivity: Are they critical in cancer? Cancer Biol Ther 10 
(2010) 942-4. 
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CHAPTER 2 
CHFR binds to and regulates MAD2 in the spindle assembly checkpoint 
through its cysteine-rich domain 
 
Abstract 
 CHFR has been implicated as a tumor suppressor in a multitude of 
cancers.  It was originally identified as a major component of the antephase 
checkpoint.  Recently, CHFR was reported to interact with MAD2, an important 
component of the spindle assembly checkpoint, where CHFR knockdown 
resulted in mislocalization of MAD2 and disruption of the MAD2/CDC20 
interaction.  To further understand how CHFR interacts with MAD2, we deleted 
key functional domains of CHFR, and investigated the effect on MAD2 binding 
and function.  Here we show that deletion of the cysteine-rich domain of CHFR 
is required for the CHFR/MAD2 interaction as well as proper localization of 
MAD2 in the cell.  Furthermore, the cysteine-rich domain deletion exhibits 
impaired ability to promote the MAD2/CDC20 interaction, leading to an 
increase in mitotic defects relative to wild type CHFR.  These data support a 
critical role for CHFR in the MAD2 spindle checkpoint.  Furthermore, these data 
establish the cysteine-rich domain of CHFR as the essential domain for the 
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CHFR/MAD2 interaction and for promoting interaction between MAD2 and 
CDC20 to inhibit the anaphase-promoting complex. 
 
 Introduction  
CHFR (Checkpoint with FHA and Ring finger) is an E3 ubiquitin ligase 
that functions as a mitotic checkpoint protein and has been implicated as a tumor 
suppressor in a wide array of cancer types [1, 2, 15].  Chfr-/- mice developed 
spontaneous lymphomas and epithelial tumors, and formed skin tumors in 
response to a DMBA treatment that did not induce tumor formation in wild type 
mice [5].  In addition, Chfr knockout (Chfr-/-) mouse embryonic fibroblasts 
(MEFs) display mitotic defects including failed nuclear segregation, lagging 
chromosomes, and failed cytokinesis, and become aneuploid over time in culture 
[5].  A similar aneuploidy and mitotic defect phenotype was observed in 
immortalized breast epithelial cells when CHFR was knocked down by siRNA 
[29].  Aneuploidy is often observed as a consequence of mitotic checkpoint 
defects.  In fact, CHFR was initially identified as an antephase checkpoint protein 
essential for triggering the mitotic stress checkpoint in response to nocodazole 
treatment [1, 15].  Subsequent studies have identified Aurora A and Kif22 as 
ubiquitination targets of CHFR, implicating CHFR in the spindle-assembly 
checkpoint occurring later in mitosis [5, 20].  
Mitotic arrest deficient 2 (MAD2) has been identified as a key protein 
responsible for detecting proper spindle attachment to kinetochores, and triggers 
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delay through inhibition of the anaphase-promoting complex (APC) when 
attachments are incomplete [51]. This inhibition occurs through binding of 
MAD2 to CDC20, which inhibits its activation of the APC [90].  While this 
checkpoint has been extensively studied, full understanding of the mechanism 
by which MAD2 and CDC20 interact to trigger the spindle checkpoint remains 
elusive.  MAD2, like CHFR, has been linked to cancer phenotypes and is often 
overexpressed in human tumors [88, 91].  Overexpression of MAD2 occurs in 
multiple tumor types and is associated with chromosome instability and poor 
prognosis [88, 91, 92].  Overexpression of MAD2 in mice produced an array of 
tumor types, including lung adenoma, hepatoma, and intestinal tumors [88]. 
Furthermore, MEF cells derived from these mice displayed chromosome 
segregation defects and increased aneuploidy relative to wild type cells [88]. 
Recently, MAD2 was identified as a CHFR-interacting protein by yeast-
two-hybrid, and this interaction was verified using cultured cells [29].  Notably, 
knockdown of CHFR via siRNA resulted in mislocalization of MAD2 during 
mitosis, and inhibited the MAD2/CDC20 interaction [29].  CHFR knockdown 
also resulted in mislocalization of BUBR1 [29], which cooperates with MAD2 to 
inhibit the APC [90].  These data implicate CHFR in regulation of the 
MAD2/CDC20 interaction, and may point to a complex role of CHFR in the 
spindle checkpoint, but further analyses supporting an interaction between 
CHFR and MAD2 have not yet been reported. 
30 
To better understand the role of CHFR in the MAD2-dependent spindle 
checkpoint, we deleted key CHFR domains and examined the effect on MAD2.  
We find that the FHA and Ring domains are not required for MAD2 binding to 
CHFR, while the C-terminal cysteine-rich domain is required for this interaction.  
Furthermore, the FHA and Ring domain deletions had no effect on MAD2-
CDC20 binding, while deletion of the cysteine-rich domain inhibited this 
interaction.  Finally, deletion of the cysteine-rich domain resulted in 
mislocalization of MAD2 in mitotic cells, leading to improper chromosome 
migration.  Together, this data suggest that CHFR binding to MAD2 is important 
for proper cellular localization of MAD2 during mitosis and effective activation 
of the mitotic spindle checkpoint. 
 
Materials and Methods 
Plasmids and Antibodies 
CHFR deletion constructs were created using the QuikChange site-
directed mutagenesis kit (Stratagene).  MAD2 antibodies were obtained from BD 
Biosciences (blotting) and Santa Cruz (Immunoprecipitation).  CHFR antibody 
was a gift from the Yu lab (University of Michigan); CDC20 antibody was from 
BD biosciences.  Anti-Flag and anti-HA antibodies were from Sigma and 
Covance, respectively.  Fluorescent secondary antibodies were purchased from 
Jackson ImmunoResearch. 
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Cell Culture and Immunoprecipitation 
HEK293T cells were obtained from ATCC and cultured in DMEM 
containing 10% FBS.  Immortalized mouse embryonic fibroblasts were a gift from 
the Yu lab (University of Michigan).  Transfection of HEK293T cells was 
performed using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol.  MEF cells were transfected by electroporation (BioRad 
Gene Pulser XCell).  Transfected cells were treated with nocodazole for 18 hours, 
then lysed with NETN buffer [5], spun at 4 °C and the supernatant was collected.  
For immunoprecipitation, lysate was incubated overnight with Protein A 
(Invitrogen), Protein G (Invitrogen) or anti-Flag beads (Sigma), and the indicated 
antibodies.  After binding, beads were washed three times with NETN buffer 
and subjected to Western blot. 
Immunofluorescence 
 After electroporation, MEFs were plated to glass coverslips and allowed to 
recover for 24 hours, then treated with nocodazole for 18 hours.  After treatment, 
cells were fixed in cold methanol for 10 minutes, then stained with the indicated 
antibodies at 1:1000 dilution in 8% goat serum/PBS for one hour.  Secondary 
antibodies were applied at 1:600 dilution for 30 minutes, followed by 1 minute of 
DAPI/PBS.  
 
Results 
The Cystein-rich domain is required for CHFR-MAD2 binding. 
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The interaction between CHFR and MAD2 was originally reported in 2008 
by Privette et al [29].  We verified this interaction by immunoprecipitation using 
antibodies against endogenous CHFR and MAD2 in HEK293T cells (Figure 2.1). 
To further examine this interaction we utilized three deletion constructs of 
CHFR.  CHFR has several reported domains including the forkhead associated 
(FHA), the RING finger (RING) and the cysteine-rich (Cys) domains (Figure 2.2) 
[1].  The FHA domain is thought to be a phosphothreonine-binding domain, 
although no binding target for the CHFR FHA domain has been reported [6].  
The RING domain is required for the ubiquitin ligase activity of CHFR [17], and 
is required for the mitotic stress checkpoint [15].  Finally, the Cys domain of 
CHFR has been identified as a protein-binding domain, required for the 
interaction of CHFR with its ubiquitination targets Aurora A and Kif22 [5, 20].  
Using co-immunoprecipitation with individual deletion constructs, we 
investigated which domain is required for MAD2 binding.  As shown in Figure 
2.3, only the CHFRΔCys mutant protein failed to pull down HA-tagged MAD2, 
while CHFRΔFHA and CHFRΔRing deletions had no effect on HA-MAD2 
binding.  This indicated that the Cys domain was likely the domain of MAD2 
binding, consistent with previous findings that the Cys domain is important for 
CHFR protein-protein interactions. 
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Figure 2.1.  CHFR binds to MAD2 in HEK293T cells.  HEK293T cell lysates were 
immunoprecipitated using anti-Chfr antibodies and blotted for MAD2 (top), and 
immunoprecipitated using anti-MAD2 antibodies and blotted for CHFR 
(bottom).  
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Figure 2.2.  CHFR deletion mutants.  This illustration depicts the CHFR deletion 
mutants utilized in this study. 
35 
 
 
 
 
 
Figure 2.3.  The MAD2 interaction with CHFR requires the cysteine-rich domain.  
Chfr-/- MEF cells were transfected with the indicated Flag-CHFR constructs and 
HA-MAD2 where indicated.  Immunoprecipitations using anti-Flag (top) and 
blotted with anti-HA are shown at the top.  The bottom two lanes show input 
protein levels.  The CHFRΔCys construct is unable to pull down any visible 
MAD2 protein, indicating that the Cys domain is critical for MAD2 binding. 
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CHFRΔCys expression cannot rescue abnormal Mad2 localization in Chfr-/- 
MEFs. 
Previous work has shown that siRNA reduction of CHFR in human cell 
lines results in mislocalized MAD2 and disruption of the MAD2-dependent 
spindle-assembly checkpoint [29].  We were able to confirm this phenotype using 
immunofluorescence of endogenous Mad2 in immortalized Chfr-/- mouse 
embryonic fibroblasts (MEFs).  While Mad2 in wild type MEFs displayed the 
characteristic punctate staining by immunofluorescence, Chfr-/- MEFs showed 
more diffuse Mad2 localization (Figure 2.4).  Transfection of GFP-tagged CHFR, 
as well as GFP-CHFRΔFHA and GFP-CHFRΔRing constructs into Chfr-/- MEFs 
restored the punctate staining, while GFP-CHFRΔCys was unable to restore 
punctate Mad2 staining in mitotic cells (Figure 2.5).  These data suggested that 
Chfr plays a role in Mad2 localization, which is dependent on binding via the 
cysteine-rich domain of Chfr. 
 
CHFRΔCys does not rescue segregation defects in Chfr-/- MEFs. 
 MAD2 functions in the cell as part of the spindle assembly checkpoint, to 
ensure proper chromosome segregation during mitosis.  Considering the Mad2 
localization changes we observed in transfected Chfr-/- MEFs, we wondered if the 
localization of Mad2 correlated to a spindle-assembly checkpoint phenotype.  
Thus, we investigated if the CHFRΔCys construct, and other deletion constructs, 
could rescue the chromosome segregation defects seen in Chfr-/- MEFs.  DAPI 
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staining of Chfr-/- and wild type MEFs indicates that Chfr-/- MEFs have a higher 
incidence of lagging chromosomes, in agreement with previous reports using 
primary MEF cells [29] (Figure 2.6).  Transfection of Chfr-/- MEFs with CHFR, 
CHFRΔFHA, and CHFRΔRing constructs were able to reduce the incidence of 
lagging chromosomes, while cells expressing CHFRΔCys had an incidence of 
mitotic defects similar to untransfected Chfr-/- cells (Figure 2.7). 
The Cystein-rich domain of CHFR is important for Mad2-Cdc20 binding. 
 The mitotic defect seen in Chfr-/- MEFs and maintained when those cells 
expressed CHFRΔCys suggests that the cysteine-rich domain of CHFR may be 
critical for proper Mad2 function.  To further investigate the effect of CHFRΔCys 
on Mad2 function, we used co-immunoprecipitation to assay the binding of 
Mad2 with Cdc20 in MEFs expressing CHFR constructs.  In agreement with 
previous data using siRNA reduction of CHFR [29], we observed a decrease in 
Mad2-Cdc20 binding in Chfr-/- MEFs relative to wild type MEFs (Figure 2.8).  
Notably, expression of CHFR in Chfr-/- MEFs increased the interaction between 
Cdc20 and Mad2 (Figure 2.9).  Expression of both CHFRΔFHA and CHFRΔRing 
constructs were co-immunoprecipitated with Mad2 at levels similar to wild type, 
while CHFRΔCys was unable to increase the Mad2-Cdc20 interaction (Figure 
2.9).  This suggests that the cysteine-rich domain is necessary for CHFR to 
enhance Mad2-Cdc20 binding, possibly through control of Mad2 localization 
during mitosis. 
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Figure 2.4.  Localization of Mad2 in wild type and Chfr-/- MEFs.  MEF cells were 
subjected to indirect immunofluorescence using anti-MAD2 antibodies.  Mitotic 
Chfr-/- cells display a more diffuse Mad2 staining than the wild type cells.  
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Figure 2.5.  The cysteine-rich domain of CHFR is required for proper Mad2 
localization.  Chfr-/-MEFs were transfected with GFP-tagged CHFR constructs 
(indicated at the left), and subjected to indirect immunofluorescence for Mad2 
staining.  While wild type CHFR, as well as the FHA and RING domain deletions 
could restore clear punctate staining to the MEF cells, GFP-CHFRΔCys failed to 
restore punctate staining.
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Figure 2.6.  Chfr-/- MEFs display a higher rate of chromosome segregation 
defects.  Wild type and Chfr-/- MEFs were enriched in mitosis and observed for 
lagging chromosomes (indicated by arrow).  DAPI staining was used to observe 
lagging chromosomes during mitosis, the incidence of this defect is indicated in 
the histogram at the bottom. 
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Figure 2.7.  The cysteine-rich domain is required to rescue the chromosome 
segregation phenotype in Chfr-/- MEFs.  Chfr-/- MEFs were transfected with GFP-
CHFR constructs indicated on the left.  DAPI staining was used to observe 
lagging chromosomes during mitosis (indicated with arrow).  Incidence of 
lagging chromosomes in mitotic cells is quantitated in the histogram at the 
bottom. 
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Figure 2.8.  Mad2 interaction with Cdc20 is impaired in Chfr-/- MEFs.  Wild type 
and Chfr-/- MEFs were lysed and the lysate subjected to immunoprecipitation 
using anti-Mad2 and blotted for Cdc20 (first row), or immunoprecipitation using 
anti-Cdc20 antibodies and blotted for Mad2 (second row) Bottom half indicates 
input levels of both proteins.  Chfr-/- MEF lysates showed reduced Cdc20 co-
immunoprecipitating with Mad2, and vice versa.  
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Figure 2.9.  The cysteine-rich domain is required for restoring the Mad2/Cdc20 
interaction to Chfr-/- MEFs.  Chfr-/- MEFs were transfected with CHFR deletion 
constructs indicated at the top.  Lysates from these cells were subjected to 
immunoprecipitation as in Figure 2.8.  While ΔFHA and ΔRING expressing cells 
display Mad2 and Cdc20 pulldown comparable to wild type expressing cells, the 
ΔCys transfected cells retained the reduced pulldown between the two proteins. 
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Discussion 
The MAD2 spindle assembly checkpoint is the focus of a wide number of 
studies.  While the complex mechanism by which MAD2 performs its function is 
not fully understood, the interaction between MAD2 and CDC20 has been 
established as a critical component of this pathway [49, 51].  MAD2 activity is 
regulated by a change in conformation between closed (active, C-MAD2) and 
open (inactive, O-MAD2) forms [93-95].  C-MAD2 is bound to MAD1 at an 
unattached kinetochore, and is thought to serve as a template for conversion of 
other O-MAD2 to C-MAD2 at the kinetochore (Figure 2.10) [96, 97].  The newly 
converted C-MAD2 then forms a diffusible complex with CDC20, BUBR1, BUB3 
and the APC [51, 58, 96, 98].  C-MAD2 in this complex may also act as a template 
for conversion of cytoplasmic O-MAD2 to C-MAD2 [96].  This complex impairs 
the CDC20-dependent activation of the anaphase-promoting complex and is 
abolished when the spindle-assembly checkpoint is satisfied [51, 58, 98].  MAD2 
phosphorylation may play a role in regulating its binding to APC and MAD1, as 
phosphorylation of MAD2 reduced the interactions in vivo [99].  Interestingly, an 
inhibitor of the spindle assembly checkpoint, p31comet binds to C-MAD2 on the 
same surface as O-MAD2, and can compete with O-MAD2 for binding to C-
MAD2, suggesting that p31comet inhibits the checkpoint by preventing conversion 
of MAD2 to its active form [96, 100-102]. 
Our data support the hypothesis that CHFR may play a role in localization 
of MAD2 to one or more of its functional complexes, and loss of CHFR or the 
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Figure 2.10.  Model of MAD2 conformational switching.  MAD2 is known to 
switch from the inactive, open form (O-MAD2) to the active, closed form (C-
MAD2), and is thought to catalyze this conformational change through 
interaction of O- and C-MAD2.  Current models consider C-MAD2 binding to 
MAD1 at the unattached kinetochore to be the first step, after which O-MAD2 
will be converted to C-MAD2 through interaction with the MAD2/MAD1 
complex.  Additionally, cytoplasmic C-MAD2 may amplify the C-MAD2 levels 
by converting free O-MAD2 to C-MAD2 away from the kinetochores. 
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cysteine-rich domain of CHFR can disrupt the MAD2 spindle-assembly 
checkpoint pathway.  In the absence of functional CHFR, MAD2 may not be 
efficiently transported to the kinetochores for activation (Figure 2.11).  This 
disruption could impair the production of active MAD2, resulting in reduced 
inhibition of the anaphase-promoting complex, effectively repressing the 
spindle-assembly checkpoint and promoting anaphase progression.  While 
CHFR has been defined as an E3 ubiquitin ligase [1], we could not see any 
measurable change in Mad2 or Cdc20 protein levels in cells expressing 
CHFRΔRing, a deletion that abolishes the ubiquitin ligase activity of CHFR 
(Figure 2.9) [15].  This suggests that the effect of CHFR on Mad2 activity is not 
dependent on ubiquitination.  However, our results suggest an important role for 
Chfr in Mad2 localization and activation. 
The cysteine-rich domain appears to be a major protein-protein interaction 
domain for CHFR, as it has been identified as the domain required for 
interactions with Aurora A, Kif22, and HDAC1 in addition to MAD2 [5, 20, 21].  
The cysteine-rich domain also contains the PAR (poly(ADP-ribose))-binding zinc 
finger (PBZ) motif, which binds to PAR-bound proteins [22].  Interestingly, PAR-
proteins accumulate on the mitotic machinery, and PAR addition to proteins is 
critical for spindle function [22, 23, 25].  It is possible that the cysteine-rich 
domain deletion is unable to localize to PAR-enriched sites, which then results in 
reduced binding to MAD2.  Alternatively, CHFR binding to MAD2 could 
precede localization to the mitotic machinery, resulting in mislocalization of 
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Figure 2.11.  A model for CHFR regulation of MAD2 in the spindle assembly 
checkpoint.  In the presence of CHFRΔCys, or in the absence of CHFR protein, 
MAD2 fails to localize to the kinetochore and does not bind CDC20 to inhibit the 
APC and trigger the spindle assembly checkpoint. 
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MAD2 when the PBZ domain is deleted.  Extensive future work will be required 
to decipher the exact mode of action of CHFR with MAD2.  
The interaction between CHFR and MAD2 represents another layer of 
complexity in the mitotic checkpoint function of CHFR, and may have important 
implications in cancer treatment.  Both MAD2 and CHFR have been implicated 
as tumor suppressors, and changes in expression of both proteins have been 
linked to tumorigenesis [5, 87].  CHFR expression is reduced by promoter 
methylation in a wide array of cancer types [2]. A small number of CHFR 
mutations have been identified in cancer cells [2, 63].  One polymorphism 
(V539M) located in the cysteine-rich domain was reported to be strongly 
associated with colorectal cancer risk [64].  Surprisingly, MAD2 overexpression 
was reported to lead to tumorigenesis in mice and was shown to correlate to 
shorter survival in lung and bone cancers, suggesting that MAD2 has multiple 
functions in mitosis, which are sensitive to changes in MAD2 dosage [88, 92, 103].  
Clearly both MAD2 and CHFR represent interesting candidates for cancer 
biomarkers.  Further understanding of the interaction between CHFR and MAD2 
may lead to increased accuracy in cancer prognoses as well as more fine-tuned 
cancer treatments in the future. 
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checkpoint through its cysteine-rich domain. Biochem Biophys Res Commun 409 
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CHAPTER 3 
CHFR protein levels may be regulated by microRNA in breast cancer lines 
 
Abstract 
 CHFR protein levels are decreased in many breast cancer lines as well as 
multiple other cancers [2, 4].  Reduced transcription of CHFR due to promoter 
hypermethylation has been observed in many cancers, however this explanation 
does not appear to apply to breast cancers [4].   Preliminary experiments 
indicated that several breast cancer lines with low CHFR protein levels contained 
high levels of CHFR mRNA, suggesting a post-transcriptional regulation of 
CHFR expression is likely to be occurring in these cells.  Several putative 
microRNA (miRNA) target sites are present in the 3’UTR of CHFR, leading to the 
hypothesis that miRNA binding may be responsible for the discord between the 
CHFR mRNA and protein levels.  Several of the miRNAs predicted to target 
CHFR have been associated with cancers or cancer phenotypes.  Utilizing a panel 
of breast cancer cell lines, we found that expression of miR-26 was high in each 
of the cell lines with high CHFR mRNA and low CHFR protein levels.  
Experiments using miR-26 inhibitors suggest a slight increase in CHFR protein 
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levels when miR-26 was inhibited, although these results were not significant.  
Further investigation is needed to determine the impact of microRNA inhibition 
on CHFR, and if microRNA inhibition is an alternate mechanism by which CHFR 
expression is lost in cancer cells. 
 
Introduction 
 CHFR is a tumor suppressor protein that is implicated in multiple cancer-
progression pathways [2, 3, 5, 89].  While significant effort has gone into 
identifying targets of CHFR, little is known about how CHFR activity itself is 
regulated.  CHFR degradation via autoubiquitination is observed in cells, and 
deubiquitination of CHFR by USP7 can stabilize CHFR protein [15, 104].  
However, there are conflicting reports regarding if CHFR protein levels are 
modulated between stages of the cell cycle [20, 52].  Recently, Stil (SCL/TAL1 
interrupting locus) was identified as the first known inhibitor of CHFR [37]. 
Castiel et al showed that Stil-/- MEFs express increased levels of CHFR, and that 
Stil increases the autoubiquitination and degradation of CHFR [37]. Stil is 
reportedly overexpressed in lung cancers [105], and thus Stil expression changes 
could account for some loss of CHFR expression in cancers. 
 CHFR protein levels are reduced in a spectrum of cancer types, and in 
most cases evidence of CHFR gene promoter methylation has been found [2]. 
However, breast cancers appear to be the exception to this trend.  A screen of 24 
breast cancer cell lines found only two lines with evidence of CHFR promoter 
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methylation [4].  An extensive study of 110 primary breast carcinoma samples 
found only one case in which CHFR promoter methylation was present [65].  
Finally, a recent study of ductal carcinoma in situ and adjacent invasive ductal 
cancer from 33 breast cancer patients found little evidence of CHFR promoter 
methylation in either tissue type (3% in ductal carcinoma in situ, none in invasive 
ductal cancer) [106].  Several alternate pathways could account for reduction in 
CHFR protein expression, including reduced mRNA or protein stability, or 
reduced gene transcription.  Of particular interest is post-transcriptional 
regulation by microRNA-based inhibition.  Many microRNA genes (designated 
“mir”) are located in regions of genome instability in cancers, and changes in 
miRNA expression have been implicated in cancer progression [107, 108].  In 
breast cancer, miRNAs have been reported to suppress metastases and 35 mir 
genes were identified on genomic regions commonly amplified or lost in breast 
cancers [107, 109-111].  We therefore hypothesized that microRNA expression 
could account for the discord observed between CHFR mRNA and protein levels 
in breast cancer cell lines, and could also represent a novel mechanism of CHFR 
regulation. 
 
Materials and Methods 
Cell culture and transfection 
 Cell lines were acquired from ATCC and grown as recommended.  50 nM 
antisense microRNA inhibitors (anti-miR miRNA inhibitors, Applied 
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Biosystems) were transfected into HEK293 cells using Dharmafect 2 reagent 
(Dharmacon) according to manufacturer’s protocol.  Cells were lysed for qPCR 
and Western blot 48 hours post-transfection. 
 
Western blot 
 Lysate samples were run on a 10% SDS-PAGE gel, and then transferred to 
PVDF.  Proteins were immunoblotted with anti-CHFR (Abnova) and anti-
GAPDH (Sigma) as a loading control.  Protein quantities were estimated using 
ImageJ software (http://rsbweb.nih.gov/ij/). 
 
Semi-quantitative RT PCR and qPCR 
 RNA was isolated using the miRNeasy kit from Qiagen.  Semi-
quantitative PCR was performed as previously described, using a touchdown 
PCR program with three cycles at 62∘, three cycles at 60∘, and eighteen cycles at 
58∘, [3].  For CHFR and GAPDH measurement, cDNA was produced using the 
Omniscript RT kit (Qiagen).  Quantitative RT-PCR was performed using Taqman 
gene expression assays (Applied Biosystems) for CHFR (Hs00946136_m1) and 
GAPDH (Hs99999906_m1) according to the manufacturer’s protocol.  For 
microRNAs, RT was performed using Taqman microRNA Reverse Transcription 
Kit (Applied Biosystems), with microRNA-specific primers, followed by qPCR 
using Taqman MicroRNA Assays (Applied Biosystems) according to the 
manufacturer’s protocol. 
54 
Results 
Discordance between mRNA and protein levels of CHFR breast cancer cell lines 
 Reduced expression of CHFR is seen frequently in breast cancers as well 
as other cancers [2]. However, unlike in other cancers in which promoter 
methylation and a few rare mutations have been found, no cause has yet been 
identified for the reduced CHFR levels in breast cancer [2, 4, 65].  To address this 
question, we utilized a panel of nine breast cancer cell (BCC) lines, as well as 
three immortalized mammary epithelial cell (IHMEC) lines, and examined the 
CHFR mRNA and protein levels in each cell type.  Semi-quantitative RT-PCR 
analysis indicated that every cell line, with the exception of the BCC DU4475, 
contained some CHFR mRNA (Figure 3.1).  Western blot analysis of CHFR 
protein showed much more variation (Figure 3.2), and suggested that mRNA 
levels in these lines do not correlate well to protein levels.  CHFR mRNA was 
also assayed using the more sensitive method of real-time PCR, the results of 
which were similar to the semi-qPCR results (Figure 3.3).  Side-by-side 
comparison of CHFR mRNA and protein measurements is indicated in Figure 
3.4.  These results indicate that CHFR mRNA and protein levels do not correlate 
well in BCC lines. 
 
The CHFR 3’UTR contains putative miRNA binding sites 
Growing evidence implicates miRNA inhibition in the regulation of gene 
expression, specifically by interfering with mRNA stability or translation [107]. 
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Figure 3.1.  mRNA levels of CHFR in breast cancer cell lines, as measured by 
semi-quantitative PCR. Quantitation of PCR products relative to GAPDH is 
shown below the gel picture. 
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Figure 3.2.  CHFR protein levels vary between breast cancer cell lines.  BCC lines 
were analyzed for CHFR protein levels by Western blot.  GAPDH protein levels 
were used as a loading control.  Below, CHFR protein levels are quantitated 
relative to GAPDH and normalized to the average of the HPV lines.  
 
. 
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Figure 3.3.  qPCR measurement of CHFR mRNA levels. CHFR levels were 
measured using qPCR and normalized to the average of the HPV lines. 
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Figure 3.4.  CHFR mRNA and protein levels do not correlate in BCC lines.  Side-
by-side comparison of mRNA levels measured by qPCR and protein levels.  
Values represent the relative expression of CHFR mRNA and protein normalized 
to GAPDH within each cell line.  The value of ‘1’ represents the average of the 
expression levels measured in HPV lines, to which each cell line was compared. 
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In cases in which translation is prevented, often seen when miRNA binds with 
imperfect base pairing [107], we expect to see low protein levels in spite of high 
mRNA levels, which we observed for multiple BCC lines.  Targetscan 
(www.targetscan.org) search of human CHFR revealed several putative miRNA-
binding sites in the 3’UTR of CHFR (Figure 3.5).  Interestingly, three of the 
implicated miRNAs with high Targetscan scores, miR-26, miR-218 and miR-
221/222, have previously been associated with cancer phenotypes (Table 3.1).  
Upregulation of miR-26, which encodes two isoforms (designated a and b), is 
associated with hypoxia and breast cancer, as well as other cancers [112, 113].  
We chose to prioritize these microRNAs in our study due to the existing links 
between their expression and cancer phenotypes. 
 
microRNA-26a and b have high expression in a subset of BCC lines expressing 
high CHFR mRNA levels and low CHFR protein levels 
 To understand the relationship between these microRNAs and CHFR 
protein expression, we first divided the BCC panel into three subsets based on 
CHFR mRNA and CHFR protein levels; high mRNA/low protein (high/low), 
high mRNA/high protein (high/high), and low mRNA/low protein (low/low). 
The designations of “high” and “low” expression indicate the levels relative to 
the average of three IHMEC lines.  No lines were identified displaying low 
mRNA/high protein, possibly due to this normalization, and the IHMEC lines 
(HPV 1-30, HPV 5-24 and HPV 4-12) are categorized to the low/low and  
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Figure 3.5.  Putative miRNA binding sites on the CHFR 3’UTR.  Targetscan 
results for CHFR indicate several putative microRNA binding sites in the 3’UTR 
of the CHFR gene.  
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miRNA Targetscan 
score 
Associated with: 
hsa-miR-26 26a: 99 
26b: 99 
Colorectal Cancer [114] 
General cancers [112] 
Hepatocellular carcinoma [115] 
Hypoxia and breast cancer [112, 113] 
Nasopharyngeal carcinoma [116] 
Thyroid carcinoma [117] 
Tongue squamous cell carcinoma [118] 
hsa-miR-218 57 ALL (leukemia) [119] 
Bladder cancer [120] 
Cervical carcinoma [121] 
Lung squamous cell carcinoma [122] 
hsa-miR-221/222 221: 68 
222: 66 
Breast Cancer [123] 
Gastric Cancer [124] 
Glioma [125] 
Hepatocellular carcinoma [126, 127] 
Ovary and bladder cancer (221) [128] 
Papillary thyroid carcinoma [129, 130] 
Prostate cancer [131] 
 
 
 
Table 3.1.  Putative CHFR-targeting miRNAs are associated with cancers and 
cancer phenotypes. 
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high/high subsets.  We examined the expression levels of miR-26a, miR-26b, 
miR-218, miR-221 and miR-222 in each of these subsets of cell lines using qPCR.  
Strikingly, each of the cell lines in the high/low subset expressed at least one 
form of miR-26 at high levels (Figure 3.6), while miR-218 and -221/222 were 
observed at both high and low levels within this subset (Figure 3.7).  miRNA 
expression levels in the low/low and high/high subsets showed no obvious 
trends (Figures 3.8 and 3.9).  This data suggest that miR-26 could be involved in 
preventing translation of CHFR mRNA, and could explain reduced CHFR 
expression in some BCC lines. 
Inhibition of miR-26 has little effect on CHFR protein levels 
 To directly examine the effect of miR-26 modulation on CHFR protein 
levels, we employed a miR antisense inhibitor to reduce the levels of miR-26a 
and miR-26b in HEK293 cells.  As illustrated in Figure 3.10, the miR-26 antisense 
inhibitor reduced the levels of miR-26a and miR-26b by approximately 90% and 
70%, respectively.  Cells that had been transfected with the miR-26 inhibitor were 
then analyzed for CHFR protein levels using western blot.  Relative to the non-
specific inhibitor, CHFR protein levels measured as increased by an average of 
15% when miR-26 was inhibited (Figure 3.11), using ImageJ.  This method of 
measuring band size and intensity is not as sensitive as required for this change 
to be considered significant.  Upon more stringent testing, miR-26 inhibition 
could support the hypothesis that miR-26 is inhibiting CHFR protein translation 
in some cells. 
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Figure 3.6.  miR-26 is expressed at high levels in cells with high CHFR mRNA 
and low CHFR protein.  Levels of miR-26a or -26b, or both are high in each cell 
line of the high/low set.  Values represent the relative expression of CHFR 
mRNA and protein normalized to GAPDH within each cell line.  The value of ‘1’ 
represents the average of the expression levels measured in HPV lines, to which 
each cell line was compared. 
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Figure 3.7.  miR-218 and miR-221/222 expression in high mRNA/low protein 
lines.  miR-218 and -221/222 do not show a trend in the high/low cell line set.  
Values represent the relative expression of CHFR mRNA and protein normalized 
to GAPDH within each cell line.  The value of ‘1’ represents the average of the 
expression levels measured in HPV lines, to which each cell line was compared. 
65 
 
 
 
 
 
Figure 3.8.  miRNA expression levels in the high mRNA/high protein cell lines.   
Values represent the relative expression of CHFR mRNA and protein normalized 
to GAPDH within each cell line.  The value of ‘1’ represents the average of the 
expression levels measured in HPV lines, to which each cell line was compared. 
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Figure 3.9.  miRNA expression levels in the low mRNA/low protein cell lines. 
Values represent the relative expression of CHFR mRNA and protein normalized 
to GAPDH within each cell line.  The value of ‘1’ represents the average of the 
expression levels measured in HPV lines, to which each cell line was compared. 
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Figure 3.10.  Inhibition of miR-26a and miR-26b by antisense inhibitors.  
Antisense miR-26 inhibitors were transfected into HEK293 cells.  Reduction of 
miR-26a and miR-26b was measured by qPCR and the magnitude of knockdown 
relative to non-specific inhibitor is depicted in the histogram. 
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Figure 3.11.  CHFR protein levels after miR-26 inhibition.  Western blot was used 
to observe CHFR protein levels in HEK293 cells after transfection with miR-26 
inhibitor, or a non-specific control inhibitor.  Bands were quantitated using 
ImageJ, and normalized band measurements are indicated for each lane.  On 
average, miR-26 inhibition increased the CHFR protein measurement by 15%. 
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Discussion 
 Regulation of transcripts by microRNAs is observed in a range of normal 
and disease-related processes including cancer [107]. Regulation of the cell cycle 
and cell proliferation are no exception [132, 133].  Expression profiles of miRNAs 
are currently studied in cancers to identify players involved in initiation and 
progression of tumors.  MicroRNA expression has been investigated in breast 
cancers, and has identified several microRNAs of interest for understanding 
disease evolution as well as for use as prognostic biomarkers [113, 134].  
Interestingly, several microRNAs have been identified that are modulated by 
estrogen receptor-α (ERα) expression in breast cancer cell lines, and some of those 
microRNAs appear to target ERα mRNA as well [135].  As estrogen receptor 
status has a major impact on efficacy of breast cancer treatment [136], an 
understanding of microRNA expression and regulation could have significant 
impact on clinical understanding of the disease. 
Here, we show data that several breast cancer cell lines express high levels 
of CHFR mRNA, while maintaining low CHFR protein levels.  One possible 
explanation for this finding is negative regulation at the level of mRNA 
translation, by microRNA binding.  Using a panel of breast cancer cell lines, we 
found an association between high expression of miR-26 and a high/low 
relationship between CHFR mRNA and protein.  We further investigated if miR-
26 binding was responsible for inhibition of CHFR protein production using 
antisense miR-26 inhibitors.  The results indicate that reduction of miR-26 in 
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HEK293 cells may result in a small increase in CHFR protein expression, lending 
support to the miR-26 inhibition model. 
 Several considerations must be made when interpreting these results.  The 
miR-26 inhibition experiment was performed using only HEK293 cells, and a 
different outcome might be seen in other cell types.  Additionally, the rapid 
growth rate of HEK293 cells limited the timeline of the experiment to 48 h post-
transfection, as samples taken beyond 48 h no longer displayed miR-26 inhibition 
(data not shown).  It is possible that this window of time is too short, and that if 
inhibition were continued a more dramatic effect could be seen.  Alternatively, 
the small amount of miRNA remaining after inhibition could be sufficient to 
inhibit CHFR expression.  We utilized IHMEC lines as a tool for normalizing the 
levels of miRNA expression measured in the breast cancer panel.  It is entirely 
possible that these lines do not represent ‘normal’ levels of miRNA due to many 
factors such as immortalization or time in culture.  Therefore the designations of 
‘high’ or ‘low’ expression must be used cautiously.  
Recent studies have identified miR-26 as a microRNA of interest in 
cancers.  Sander et al demonstrated that repression of miR-26a by the oncogene c-
MYC resulted in increased expression of Enhancer of Zeste Homolog 2 (EZH2), a 
protein that regulates gene expression and is a known oncogene [137].  A study 
of colorectal cancer cell lines identified miR-26b as a microRNA that was 
significantly downregulated in colorectal cancer cell lines, and overexpression of 
miR-26b reduced the growth of these cells [114]. Additionally, CHFR was 
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identified as a likely target of miR-26b in these cells, although the growth 
suppression phenotype seen in miR-26b overexpressing cells is opposite of what 
would be expected for an inhibitor of CHFR [114]. This most likely reflects the 
complexity of the regulation by microRNAs, and could be a result of miR-26 
having different effects in different tissue types. 
 Several other explanations for loss of CHFR in breast cancer lines are 
possible.  Two publications have reported evidence that CHFR promoter 
methylation is rare in breast cancers [4, 65], and the presence of high mRNA 
levels in some BCC lines supports this finding.  However, each study utilized 
only one method of testing for promoter methylation, and methylation might 
have been observed in cell lines with low CHFR mRNA levels if multiple 
methods were utilized.  It is possible that CHFR mRNA stability is altered by 
factors other than miRNA, such as altered binding of an unknown protein that 
targets CHFR mRNA for degradation.  This could occur through mutation of 
binding sites on the CHFR mRNA, or altered activity of the binding protein.  
Possibly more likely is alteration of CHFR protein stability, through loss or 
mutation of USP7, which deubiquitinates and stabilizes CHFR protein [104], or 
through an increase in Stil activity, which increases ubiquitination and 
degradation of CHFR protein. To our knowledge, levels of these proteins in 
breast cancer lines have not been measured.  Examination of the expression and 
mutation status of USP7 and Stil in BCC lines with low CHFR levels could lead 
to a new hypothesis for the cause of CHFR loss in breast cancer lines.  It may turn 
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out that multiple mechanisms of CHFR loss are occurring independently in 
breast cancers, and that miRNA inhibition may only be a factor in a subset of 
BCC lines. 
 Clearly more experiments are needed to fully understand the role of 
microRNA inhibition in regulating CHFR expression.  First steps should include 
overexpression of miR-26 in cells to examine if an increase in miR-26 will result 
in a decrease in CHFR protein levels.  Expression constructs linking the CHFR 
3’UTR to a fluorescent reporter can be used to measure the effect of miRNA 
modulation on protein expression, and miRNA targeting could be verified 
through mutation of the target sites.  Finally, the impact of miR-26 expression 
modulation on cancer progression phenotypes in BCC lines would be extremely 
informative regarding the impact of miR-26 on breast cancer progression.  
Further study of this pathway could advance understanding of CHFR expression 
loss in breast cancers and open doors to new breast cancer treatments in the 
future. 
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CHAPTER 4 
Conclusions 
 
CHFR plays a role in the spindle assembly checkpoint through MAD2/CDC20 
CHFR was originally identified as an antephase checkpoint protein 
important for cell cycle delay in response to microtubule stress before 
commitment to mitosis [1]. Privette et al reported that CHFR could bind to and 
appeared to regulate the function of MAD2, implicating CHFR in a second cell 
cycle checkpoint.  The interaction between MAD2 and CDC20 has been 
established as a critical component of the spindle assembly checkpoint pathway 
important for maintaining genome stability [49, 51].  This interaction impairs the 
anaphase-promoting complex through CDC20, and is abolished when proper 
spindle attachment to kinetochores is achieved [51, 58, 98]. 
Our data show that loss of CHFR or the cysteine-rich domain of CHFR can 
disrupt the MAD2 spindle-assembly checkpoint pathway.  We show that the 
cysteine-rich domain of CHFR, which includes the PBZ domain, was required for 
CHFR/MAD2 interaction.  Furthermore, CHFRΔCys expression in Chfr-/- MEF 
cells resulted in mislocalization of Mad2, impairing the interaction of Mad2 and 
Cdc20, and increasing the incidence of chromosome segregation defects.
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In the absence of functional CHFR, MAD2 may not be efficiently 
transported to the kinetochores for activation (Figure 2.11), allowing the spindle 
assembly checkpoint to be bypassed.  We were unable to show that the punctate 
localization of Mad2, which is lost in the Chfr-/- cells, is in fact at the kinetochore, 
however there is a clear mislocalization of Mad2 observed when Chfr is lost 
(Figure 2.4).  This disruption could impair the production of active MAD2, 
resulting in reduced inhibition of the anaphase-promoting complex, effectively 
repressing the spindle-assembly checkpoint and promoting anaphase 
progression.  The lack of phenotype observed in the CHFRΔFHA and 
CHFRΔRING expressing cells is of particular interest, because these two domains 
have been shown to be critical to CHFR function in the antephase checkpoint [1, 
15].  This also suggests that the effect of CHFR on MAD2 activity is not 
dependent on ubiquitination, and must be occurring by some other mechanism. 
The cysteine-rich domain appears to be a major protein-protein interaction 
domain for CHFR, important to the interactions of CHFR with several 
downstream targets including MAD2 [5, 20, 21].  The cysteine-rich domain also 
contains the PAR (poly(ADP-ribose))-binding zinc finger (PBZ) motif, which 
binds to PAR-bound proteins [22].  Interestingly, PAR-proteins accumulate on 
the mitotic machinery, and PAR addition to proteins is critical for spindle 
function [22, 23, 25].  This suggests that CHFR may depend on PAR-binding for 
some or all of its functions. 
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Significance 
The data presented in Chapter 2 enhance our understanding of CHFR 
function by implicating CHFR in the spindle assembly checkpoint and indicate 
that the function of CHFR is not solely ubiquitination-related.  CHFR interaction 
with MAD2 appears to be critical for MAD2 localization, and also MAD2 
function in the spindle checkpoint.  The interaction between CHFR and MAD2 
represents another layer of complexity in the mitotic checkpoint function of 
CHFR, as well as MAD2.  
Furthermore, the requirement of the cysteine-rich domain of CHFR but 
not the FHA or RING domains for MAD2 regulation indicates a more important 
role for the cysteine-rich domain than previously recognized.  This domain has 
been understood to function in CHFR ubiquitination target recognition, however 
MAD2 does not appear to be ubiquitinated by CHFR.  As the only domain found 
to affect MAD2-related function, the cysteine-rich domain, may have other 
properties important for MAD2 localization and activation. 
Future work will be needed to determine the full function of the CHFR 
cysteine-rich domain.  The presence of the PBZ domain points to PAR binding as 
a mechanism for CHFR target interactions.  However, the cysteine-rich domain 
extends significantly beyond the PBZ domain, and it is well conserved between 
mouse and human [1, 22].  Conservation of this domain suggests that it may 
have an important function itself, and individual deletions of the PBZ domain or 
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the cysteine-rich domain outside of the PBZ domain will be needed to determine 
if this is the case.  
Ahel et al have demonstrated that the PAR-binding function of CHFR is 
necessary for checkpoint activation, and inhibition of PARP also inhibited 
checkpoint activation [22].  While CHFR was shown to bind PAR [22], no PAR-
modified substrates of CHFR have been identified, and identification of such 
substrates would enhance our understanding of CHFR function.  Previous 
studies have concluded that the cysteine-rich domain of CHFR is not required for 
its growth inhibitory function [9]. Coupled with the data presented here 
indicating that the ubiquitin ligase function of CHFR is not required for 
regulation of MAD2, it seems that CHFR may have multiple functions that are 
dependent on distinct domains of the protein.  
The mechanism of CHFR regulation of MAD2 is another question raised 
by this work.  CHFR could be critical for MAD2 activation, and it would be 
interesting to examine if the levels of O-MAD2 and C-MAD2 are altered in cells 
lacking CHFR or expressing the ΔCys construct.  Additionally, existing MAD2 
mutants that favor the active conformation [97] could be used to test if 
expression of C-MAD2 can bypass the requirement for the CHFR cysteine-rich 
domain and attenuate the phenotypes shown in this work as well as tumor-
related phenotypes seen in cancer cells lacking CHFR.  
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Loss of CHFR in cancer may occur by multiple pathways 
 CHFR protein levels are decreased in many cancers including breast 
cancers [2, 4].  CHFR promoter hypermethylation is observed in most cancer 
types, but has not been observed in breast cancers [2, 4].  In addition a small 
number of CHFR mutations have been identified, however these mutations are 
exceedingly rare [2]. 
 In Chapter 3, evidence is presented that microRNA inhibition may be 
responsible for reduced CHFR levels in breast cancer cell lines.  Investigation of 
mRNA and protein levels in a BCC panel indicates that the amount of mRNA 
does not correlate as expected to protein levels in several of the BCC lines.  
Additionally, cells in which high CHFR mRNA levels are accompanied by low 
CHFR protein levels display high expression of miR-26.  This suggests that 
translation of CHFR protein may be inhibited by miR-26.  Finally, preliminary 
evidence suggests that reduction of miR-26 in HEK293 cells could increase CHFR 
protein levels.  These data indicate that microRNA pathways may be relevant to 
CHFR regulation, and could have special relevance to breast cancers.  
microRNA inhibition of gene expression represents a significant increase 
in the complexity of the information carried by the genome [107].  MicroRNA 
expression has been investigated in breast cancers, and these studies have 
identified several microRNAs with potential to be disease biomarkers [113, 134].  
This work is not the first to identify miR-26 as a microRNA of interest in cancer, 
lending support to the idea that it may be involved in CHFR regulation.  miR-26b 
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was observed to be downregulated in colorectal cancer lines, and overexpression 
of miR-26b reduced the growth of these cells [114].  Additionally, CHFR was 
identified as a likely target of miR-26b in these cells [114].  However, we would 
expect that downregulation of CHFR by miR-26b would increase cancer-related 
phenotypes, while a decrease in growth was observed when miR-26b was 
overexpressed [114].  It is likely that the effect of miR-26 on cellular phenotypes 
is complex, involving multiple target genes, and different effects could be seen 
based on tissue-specific factors. 
 
Significance 
 The work described in Chapter 3 forms the basis for further studies of 
microRNA regulation of CHFR.  The association between apparent mRNA 
transcription levels and miR-26 expression implicates miR-26 in regulation of 
CHFR in breast cancer lines.  This association is particularly interesting in the 
context of breast cancers in which the basis for reduced CHFR protein levels is 
unexplained, and could have implications for other cancer types as well.  In 
addition, this association may be relevant to CHFR function in normal cells as 
well.  
Further insight into the regulation of CHFR could inform both 
developmental biology and cancer biology fields.  If miR-26 were found only to 
affect CHFR levels in cancers originating from the breast, it may indicate that 
tissue-specific factors were at play.  miR-26 inhibitors could be explored as a 
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novel treatment option for patients displaying aberrantly high miR-26 expression 
in tumors.  Further study of miRNA impact on CHFR could lead to a better 
understanding of CHFR regulation in normal cells as well as in breast cancer 
cells, and ultimately bring about more effective new treatments for cancer 
patients. 
 
Future Directions 
CHFR functions as a regulator of the spindle assembly checkpoint 
The data shown here raise several new questions about CHFR function in 
the spindle checkpoint as well as the mechanisms regulating CHFR function 
itself.  Further understanding of these properties could have significant impact 
on cancer treatment; so future work should include investigations into the 
properties of primary cancer samples and cell lines. 
Many questions remain about the interaction between MAD2 and CHFR.  
While the interaction between the two proteins has been verified in this work, we 
do not know if this interaction is direct or occurs through a complex of proteins.  
Purified proteins must be used to determine if this interaction is indeed direct.  If 
not, identification of the CHFR and MAD2 interacting protein could help to 
explain the mechanism by which CHFR impacts MAD2 localization and 
function.   
Additionally, we have not identified the point in the MAD2 signaling 
pathway that the CHFR interaction is occurring.  Based on the mislocalization of 
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Mad2 in Chfr-/- MEFs, and the reduction of the Mad2-Cdc20 interaction, we 
hypothesize that CHFR disrupts kinetochore localization and activation of Mad2 
in mitosis.  However, this mislocalization could be occurring after Mad2 
activation, or it could be a result of Mad2 stabilization in the cell.  Localization of 
CHFR relative to MAD2 could be examined using a very sensitive system such as 
FRET to determine if CHFR is bound to MAD2 at the kinetochores, or in the 
cytoplasm, or both.  This will also lend insight into the mechanism by which 
CHFR regulates MAD2; does it simply affect MAD2 localization and therefore 
impact activation of MAD2, or is CHFR involved with MAD2 after activation as 
well?  
We show evidence that MAD2 function is decreased in the absence of 
functional CHFR, and that the localization of MAD2 is also affected, suggesting 
that MAD2 fails to localize to the kinetochore to be activated.  However, much 
more data is required to support this model.  The conformation of MAD2 when 
bound to CHFR should be examined to identify where in the cycle of MAD2 
CHFR is functioning.  Furthermore, the conformation of MAD2 in the 
absence/presence of functional CHFR should be tested, to determine if C-MAD2 
levels are in fact reduced when CHFR is absent or unable to bind. 
The ability of MAD2 expression, or conformational mutants of MAD2, to 
compensate for a lack of CHFR could be explored with regard to the 
chromosome instability phenotype shown here.  Mutants of MAD2 that favor 
one conformation over the other have been identified and could lend insight into 
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the specific impact of CHFR loss or mutation on MAD2 function, through rescue 
studies of phenotypes such as increased incidence of lagging chromosomes.  
Clearly the work here is merely the jumping off point for extensive inquiry into 
the role of CHFR in the MAD2-dependent spindle assembly checkpoint. 
While the FHA and RING domain deletion constructs did not impact 
MAD2 localization, MAD2 interaction with CDC20, or the incidence of lagging 
chromosomes, it is possible that these domains still play a role in MAD2 
function, for example as negative regulators of MAD2.  The model for MAD2 
deactivation involves p31comet, which competes for binding sites on C-MAD2 to 
prevent conversion of O-MAD2 to C-MAD2 [100, 102].  This model implies that 
there is a mechanism to turn over C-MAD2 that has already been made.  CHFR 
could be active in that process, by ubiquitination of C-MAD2, or other proteins 
that effect MAD2.  Such an effect would not have been observed in our tests.  
Thus, MAD2 ubiquitination, and the effect of CHFR deletions on MAD2 stability 
should be closely examined. 
 Finally, the role of the PBZ domain of CHFR in the MAD2 spindle 
assembly checkpoint, as well as the early mitotic checkpoint, is a critical question 
in the understanding of CHFR function.  PAR modifications are enriched at the 
mitotic spindle, and reduction of PAR has been shown to disrupt the mitotic 
spindle structure [25, 26].  ADP-ribose chains have been hypothesized to have a 
role in the mechanics of spindle movement as well [138].  While the existence of 
PAR modifications has been known for quite some time, how this modification 
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regulates cellular processes is still not understood, and few PAR-binding 
proteins have been identified.  The importance of the PBZ domain of CHFR in its 
mitotic checkpoint functions suggests that PAR recognition could play a critical 
role in CHFR function.  MAD2, as well as several other CHFR substrates, 
interacts with CHFR in a cysteine-rich domain-dependent fashion.  The obvious 
next question is; does CHFR interact with MAD2 through the PAR-binding 
properties of its PBZ domain?  Mutation of the PBZ domain of CHFR should be 
used to determine the importance of PBZ to MAD2 binding.  In addition, 
poly(ADP-ribose)-specific antibody could be utilized to test purified MAD2 for 
PAR modification.  It may also be that the PBZ domain is important not for 
CHFR/MAD2 interaction, but for proper localization of MAD2 after it is bound 
by CHFR.  Therefore, additional tests of the effect of the PBZ-mutated CHFR on 
MAD2 localization and function (similar to those described in Chapter 2), would 
be informative.  These studies are particularly interesting given PARP inhibitors 
are currently being tested as chemotherapeutic treatments for cancers [139, 140].  
If PAR is indeed found to play a role in CHFR’s spindle function, further tests of 
PARP inhibition on this function would be extremely valuable for 
chemotherapeutic development. 
 
CHFR expression loss in breast cancer 
Our data suggest that miR-26 could be a factor resulting in the loss of 
CHFR protein expression in some breast cancers.  However, much more work is 
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required to determine if miR-26 indeed plays a role in CHFR expression 
regulation.  The increase in CHFR protein levels we observed after miR-26 
inhibition was minimal, and more sensitive assays, such as detection using 
fluorescent probes, should be used to validate this preliminary result.  This 
should also be confirmed in multiple cell lines.  Perhaps the more successful 
experiment will be the converse, overexpressing miR-26 in CHFR expressing cell 
lines with the hope of observing a reduction in CHFR protein levels.  It may be 
easier to observe and measure a reduction in CHFR levels than to measure an 
increase above a level of expression within the cells.  It is possible that the impact 
of miR-26 in HEK293 cells is minimal, making it a poor cell line for miR-26 
inhibition experiments.  In contrast, the overexpression experiment does not 
depend on CHFR inhibition by endogenous miR-26 occurring in the cell line 
tested.  The easily-transfected HEK293 cell line could be utilized in this assay, as 
well as any other cell line in which CHFR protein is present in observable 
quantities.  
Furthermore, direct study of the effect of miR-26 on the 3’UTR of CHFR 
should be performed using a construct containing a reporter gene followed by 
the CHFR 3’UTR.  Using this tool, the effects of up and down-regulation of miR-
26 could be quantitatively measured, and mutation of the putative miR-26 
binding site can be performed to verify the role of miR-26.  Clinical relevance 
should also be examined by measuring miR-26 levels in primary breast cancers 
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in which CHFR loss is observed, ideally in comparison to matched normal 
tissues. 
The microRNA inhibition of CHFR also raises questions related to cancer 
treatment, specifically if miR-26 levels could be utilized as biomarkers for 
determining the proper course of treatments in cancers.  Examination of the 
relationship between miR-26 levels and sensitivity to microtubule-targeting 
drugs could be performed in BCC lines, to determine if a correlation exists.  
CHFR loss by promoter methylation has been extensively examined as a marker 
for sensitivity to microtubule-targeting chemotherapeutics [89]. As we know, 
CHFR promoter methylation is not observed in many breast cancers with CHFR 
expression loss, so other tests are needed to determine CHFR status.  
Measurement of microRNA levels may be useful as a surrogate test for CHFR 
expression, especially in combination with tests of CHFR mRNA levels, to 
determine the most promising course of therapy for the patient. 
It is also possible that miR-26 does not affect CHFR protein expression.  
As mentioned above, the change in CHFR levels after miR-26 inhibition was not 
significant.  Furthermore, the subcategories of BCC lines we used were 
determined by comparing BCC lines to immortalized human mammary 
epithelial cell (IHMEC) lines, which may not be an appropriate normalization 
method.  Considering that the IHMEC lines are immortalized, and have been 
passaged over time, the expression levels of CHFR, as well as of miR-26, may not 
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be a good representation of expression levels in vivo.  Therefore, other 
explanations for the reduced expression of CHFR should be explored. 
While we only observed a correlation between reduced CHFR translation 
and miR-26 expression, other microRNAs such as miR-218 or miR-221/222 could 
also be involved in CHFR regulation and should be examined as outlined for 
miR-26 above.  In addition, more careful studies using multiple methods to test 
for CHFR promoter methylation should be performed.  Promoter methylation 
could account for low CHFR mRNA expression, although some of our cell lines 
express CHFR mRNA at high levels suggesting that promoter methylation is not 
occurring in those cells. 
Of particular interest for CHFR expression regulation are the proteins Stil 
and UBC7, which are known to affect CHFR ubiquitination and degradation.  
Changes in expression levels of these CHFR regulatory proteins should be 
explored as a mechanism responsible for CHFR loss in the BCC lines.  These 
proteins are of particular interest because of their previously identified role in 
regulating CHFR protein levels.  However, there may be other proteins also 
involved in CHFR protein stability, studies to determine the CHFR protein 
stability in BCC lines should also be performed. 
 
CHFR as a tumor suppressor and cancer biomarker 
CHFR has been identified as a tumor suppressor through studies of 
knockout mice, with support from studies showing CHFR loss in many cancer 
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types[2, 5].  To better understand how CHFR functions as a tumor suppressor, 
the impact of individual domain deletions on cancer-related phenotypes should 
be examined.  The importance for each of the CHFR functional domains in the 
tumor suppressor function of CHFR is not known.  While the FHA and RING 
domains have been identified as domains essential for the early mitotic 
checkpoint function of CHFR [1, 15], our data suggest that these domains are not 
essential for the spindle-assembly checkpoint function.  Additionally, our work 
did not examine the impact of the ΔCys mutation on tumorigenic phenotypes, 
such as aneuploidy, motility, invasion, or growth rate.  One question that is 
raised by this data is: is the cysteine-rich domain of CHFR actually required for 
tumor suppression in cells?  It may be that the effects we observe on MAD2, and 
the phenotype of lagging chromosomes, ultimately do not lead to aneuploidy or 
other cancer-related phenotypes.  To answer this question, CHFRΔCys could be 
expressed stably in Chfr-/- MEFs and the CHFR-lacking BCC line Hs578T, and 
examined for aneuploidy over time. 
The FHA domain is known to function as a dominant negative, inhibiting 
the function of CHFR at the antephase checkpoint and resulting in a high mitotic 
index in a cancer cell line [1], however we did not see any effect of FHA deletion 
in our MAD2 studies. In addition, the RING domain of CHFR is required for the 
E3 ubiquitin ligase activity of CHFR but deletion of the RING domain did not 
affect MAD2 in our studies.  This supports the hypothesis that the multiple 
functions of CHFR are dependent on discreet domains of the protein, and 
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suggests that each domain may have a different impact on tumor-related 
phenotypes.  To that end, studies of the ability of deletions of each domain to 
rescue these cellular phenotypes in Hs578T and Chfr-/- cells can be performed.  In 
Hs578T cells, addition of wild-type CHFR resulted in reduction of the mitotic 
index, growth rate, motility and invasiveness of cells [3].  The effectiveness of the 
CHFR deletion constructs in producing these effects could be examined to gain 
insight into the mechanisms of the tumor suppressive functions of CHFR, and 
would help to clarify the importance of each CHFR function to tumor 
suppression.  In addition, cells stably expressing CHFR deletion mutants or wild 
type CHFR could be tested for tumorigenicity in vivo by injecting the cells into 
nude mice. 
In addition, the role of the PBZ domain in CHFR function is particularly 
interesting, considering that PARP inhibitors are currently in clinical trials for the 
treatment of breast and ovarian cancers [139, 140].  These studies are targeted at 
cancers deficient in DNA repair pathways, but understanding the impact of 
PARP inhibitors on tumors that have lost or retained CHFR could lead to more 
effective, personalized treatment for each patient. 
Finally the role of CHFR itself as a biomarker for prognosis or treatment 
efficacy in breast cancers should be more closely examined.  Using patient 
samples and histories, correlations between CHFR protein expression and 
chemotherapeutic response (particularly to microtubule-targeting drugs), tumor 
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stage, metastases and recurrence can be measured for breast cancer, as is 
currently being done for other cancer types. 
 
Summary 
CHFR is clearly an important tumor suppressor involved in cancers of 
many types.  The work presented here raises many questions about the role of 
CHFR in the spindle assembly checkpoint, and offers one possibility to explain 
the loss of CHFR in breast cancers.  While several studies of the clinical relevance 
of CHFR loss have been performed, further study of the tumor suppressive 
functions of CHFR, as well as the mechanisms by which CHFR activity is 
regulated, is needed.  Future work will aim to better understand the 
mechanism(s) by which CHFR prevents tumorigenesis, and to develop new and 
more effective cancer treatments.  
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